Breaking News, Collaborations & Alliances

Sanofi-Aventis, Roche Sign Pact

Sanofi-Aventis has signed an agreement with Roche concerning the production of shikimic acid by fermentation for Roche’s Tamiflu supply chain. Shikimic acid is the key raw material for the manufacture of Tamiflu’s active ingredient (oseltamivir). Under the terms of the agreement, Sanofi-Aventis will supply Roche exclusively with the shikimic acid obtained. The shikimic acid will be produced in the Saint-Aubin-les-Elbeuf plant in France. This site, covering 18 hectares, has a fermentation capacity of 4000 m(3), and employs 270 staff.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters